Research programme: anticancer therapeutics - MNLpharma/ZetiqAlternative Names: Anticancer therapeutics research programme - MNLpharma/Zetiq
Latest Information Update: 25 May 2007
At a glance
- Originator MNLpharma; Zetiq Technologies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 Jul 2003 Preclinical trials in Cancer in United Kingdom (unspecified route)